Immunogenicity and safety of a combined diphtheria, tetanus, 5-component acellular pertussis, inactivated poliomyelitis, Haemophilus type b conjugate vaccine when administered concurrently with a pneumococcal conjugate vaccine: A randomized, open-label, phase 3 study

Vaccine

Volumn 29, Issue 11, 2011, Pages 2212-2221

  Bernstein, Henry H ^a   Noriega, Fernando ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b SANOFI PASTEUR   (France)

Author keywords

DTaP5 IPV Hib vaccine (DTaP5 IPV Hib); Pentacel; Pneumococcal vaccines

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA VACCINE; ENERGIX B; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PENTACEL; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; BRONCHIOLITIS; COUGHING; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFANT; INJECTION SITE DISCOLORATION; INJECTION SITE SWELLING; INJECTION SITE TENDERNESS; MALE; MULTICENTER STUDY; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MALE; PNEUMOCOCCAL VACCINES; POLIOVIRUS VACCINE, INACTIVATED; UNITED STATES; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 79951809811     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.037     Document Type: Article

References (23)

1. Centers for Disease Control and Prevention (CDC) Recommended immunization schedules for persons aged 0 through 18 years-United States, 2010. MMWR 2010, 58(51 & 52):1-4.
2. Centers for Disease Control and Prevention (CDC), Combination vaccines for childhood immunization, Recommendations of the Advisory Committee on Immunization Practices (ACIP), The American Academy of Pediatrics (AAP), The American Academy of Family Physicians (AAFP). MMWR Recomm Rep 48[RR-5]: 1-14; 1999.
3. Marshall G.S., Happe L.E., Lunacsek O.E., Szymanski M.D., Woods C.R., Zahn M., et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J 2007, 26(6):496-500.
4. Happe L.E., Lunacsek O.E., Marshall G.S., Lewis T., Spencer S. Combination vaccine use and vaccination quality in a managed care population. Am J Manag Care 2007, 13(9):506-512.
5. Happe L.E., Lunacsek O.E., Kruzikas D.T., Marshall G.S. Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population. Pediatr Infect Dis J 2009, 28:98-101.
6. Centers for Disease Control and Prevention (CDC). ACIP provisional recommendations for the use of combination vaccines. Available: [accessed 12.10.09]. http://www.cdc.gov/vaccines/recs/provisional/downloads/combo-vax-Aug2009-508.pdf.
7. Mills E., Gold R., Thipphawong J., Barreto L., Guasparini R., Meekisonet W., et al. Safety and immunogenicity of a combined five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus b conjugate vaccine administered to infants at two, four and six months of age. Vaccine 1998, 16(6):576-585.
8. Scheifele D.W., Halperin S.A., Rubin E., Tapiero B., Guasparini R., Meekison W., et al. Safety and immunogenicity of a pentavalent combination vaccine (diphtheria, tetanus, acellular pertussis, polio, and Haemophilus influenzae type b conjugate) when administered as a fourth dose at 15 to 18 months of age. Hum Vaccin 2005, 1(5):180-186.
9. Guerra F.A., Blatter M.M., Greenberg D.P., Pichichero M., Noriega F.R. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial. Pediatrics 2009, 123(1):301-312.
10. Schmitt H.J., Faber J., Lorenz I., Schmole-Thoma B., Ahlers N. The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine. Vaccine 2003, 21(25-26):3653-3662.
11. Partridge S., Alvey J., Bernstein H., Blatter M., Bottenfield G., Guerrero J., et al. Safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated polio vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine. Vaccine 2007, 25(10):1806-1813.
12. Knuf M., Habermehl P., Cimino C., Petersen G., Schmitt H.J. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTaP-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine 2006, 24(22):4727-4736.
13. Shinefield H.R., Black S., Ray P., Chang I.H., Lewis N., Fireman B., et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 1999, 18(9):757-763.
14. ClincalTrials.gov Web site. Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00772928?term=M5A07&rank=1 [accessed 29.04.10].
15. Pentacel [prescribing information]. Swiftwater, PA, USA: Sanofi Pasteur Inc.; 2008. Available: https://www.vaccineshoppe.com/image.cfm?doc_id=11169&image_type=product_pdf [accessed 27.04.10].
16. Prevnar [prescribing information]. Philadelphia, PA, USA: Wyeth Pharmaceuticals Inc.; 2008. Available: http://www.wyeth.com/content/showlabeling.asp?id=134 [accessed 27.04.10].
17. 21 Code of Federal Regulations 312.32(a); 2008.
18. Van Savage J., Decker M.D., Edwards K.M., Sell S.H., Karzon D.T. Natural history of pertussis antibody in the infant and the effect on vaccine response. J Infect Dis 1990, 161(3):473-479.
19. Scheifele D.W., Halperin S.A., Smith B., Ochnio J., Meloff K., Duarte-Monteiro D. Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP. IPV/PRP-T Hib and hepatitis B vaccines in infants 2-7 months of age. Vaccine 2006, 24(12):2057-2064.
20. Public Health Agency of Canada Immunization coverage against invasive pneumococcal disease among children in the capital health region of Alberta. Can Commun Dis Rep 2005 March, 15(31):65-68.
21. Powis J.E., Church D., Macdonald J., Scheifele D., Pitchko J., Rose S., et al. Impact of differing provincial Pneumococcal vaccination programs on invasive Pneumococcal disease in children. Presented at 44th annual interscience conference on antimicrobial agents and chemotherapy 2004.
22. Le Saux N., Barrowman N.J., Moore D.L., Whiting S., Scheifele D., Halperin S. Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT. Pediatrics 2003, 112(5):e348-e353.
23. Center for Biologics Evaluation and Research (CBER). Vaccines licensed for immunization and distribution in the United States. FDA. Updated October 15, 2007. Available at [accessed 14.10.09]. http://www.fda.gov/Cber/vaccine/licvacc.htm.